Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01, R21 Clinical Trial Optional)

Funding Agency:
National Institutes of Health

The purpose of this notice of funding opportunity (NOFO) is to support translational and clinical research to (1) advance precision medicine in pregnant persons, lactating persons, and children through the development of novel tools, models, and other technologies that could have a direct clinical or health impact; (2) enhance the understanding of the underlying mechanisms of drug action, including the role of pediatric ontogeny and the dynamic physiological changes that occur during pregnancy and lactation; and (3) discover and develop novel therapeutics or enhance the usage of existing drugs or drug repurposing for safer and more effective medications in pregnant and lactating persons, neonates, and children. The overall goal is to improve safe and effective precision therapeutics for pregnant and lactating persons, fetuses, neonates, and children, including those with disabilities.

Although this funding opportunity uses the R01 grant mechanism, it runs in parallel with a program announcement of identical scientific scope, PAR-23-131, which uses the R21 grant mechanism.


  • Letter of Intent Deadlines: 30 days prior to the applicable receipt date
  • R01 Deadlines:  Feb. 5, Jun. 5, Oct. 5
  • R21 Deadlines: Feb. 16, Jun. 16, Oct. 16

PAR-23-130 Expiration Date: May 08, 2026




Medical - Translational

External Deadline

February 5, 2024